New York, Jan 23, 2026, 05:30 EST — Premarket
- Regencell Bioscience shares climbed roughly 16% in premarket action, following a 40% surge in the previous session.
- Thursday’s rally saw volume surge sharply, pushing prices through a broad trading range.
- Traders are eyeing Friday’s open, looking for volatility to ease and any fresh company disclosures.
Regencell Bioscience Holdings Ltd shares climbed 16.3% to $35.77 in premarket trading Friday, building on a steep rise from the day before.
That’s important since premarket trading—before the 9:30 a.m. ET open—can amplify price swings, particularly in stocks that are already volatile during regular sessions.
The stock jumped 40.4% on Thursday, closing at $30.77 after trading between $20.81 and $31.50, per price data.
As of Friday, Regencell’s market cap stood near $15.2 billion, according to data from .
Regencell remains at an early stage. Its most recent annual report states the company has “no saleable products” and has yet to earn any revenue from product sales. It also warned of “extreme price and volume fluctuations” that don’t necessarily reflect operating results. SEC
It also flagged the risk of a “short squeeze.” That happens when short sellers—those betting on a price drop—scramble to buy shares to cover their positions, pushing the price higher in the process.
Thursday’s jump came without any new company announcement. Regencell’s investor-relations page lists its latest press release from Oct. 31, 2025, announcing the filing of its annual report. Its SEC filings on the same site show no updates beyond that.
The risk is straightforward: a sharp run can flip just as fast. Thursday’s wide swings showed this clearly, and premarket gaps often fail to hold once heavier liquidity arrives.
Traders will keep an eye on whether the stock hits volatility pauses at the open — brief trading halts that activate during sharp moves — and look for any company statement or filing clarifying the recent swings.
